Hjem › Hjernetumorer › California › Los Angeles
Kliniske studier for Hjernetumorer i Los Angeles, CA
16 studier for Hjernetumorer søker deltakere på steder i og rundt Los Angeles (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII
RekruttererFase 2
- Cedars-Sinai Medical Center, Los Angeles
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
RekruttererFase 1/2
- University of Southern California, Los Angeles
Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
RekruttererFase 1/2
- Cedars-Sinai Medical Center, Los Angeles
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
RekruttererFase 1/2
- The Angeles clinic - A cedars SINAI AFFILIATE, Los Angeles
- USC Norris Comprehensive Cancer Center, Los Angeles
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
RekruttererFase 2
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
A Phase 1/1b Study of IAM1363 in HER2 Cancers
RekruttererFase 1
- USC Norris Comprehensive Cancer Center, Los Angeles
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
RekruttererFase 1/2
- California Research Institute, Los Angeles
A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases
RekruttererFase 2
- Univ. of California Los Angeles, Los Angeles
Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).
RekruttererFase 2
- Children's Hospital Los Angeles, Los Angeles
REMASTer: REcurrent Brain Metastases After SRS Trial
Rekrutterer
- UCLA, Los Angeles
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RekruttererFase 1/2
- University of California Los Angeles, Los Angeles
CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children
RekruttererFase 1
- Children's Hospital Los Angeles, Los Angeles
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
RekruttererFase 1
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
Advanced Magnetic Resonance Imaging for the Identification of Recurrent Brain Tumors and Radiation Necrosis
Rekrutterer
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
RekruttererFase 3
- USC / Norris Comprehensive Cancer Center, Los Angeles
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
RekruttererFase 2
- Cedars-Sinai Medical Center - Samuel Oschin Comprehensive Cancer Institute, Los Angeles
Hjernetumorer-studier i andre byer
- Houston, TX35 studier
- Boston, MA28 studier
- New York City, NY25 studier
- Washington, DC20 studier
- Miami, FL15 studier
- Durham, NC14 studier
- St. Louis, MO12 studier
- Rochester, MN11 studier
- Chicago, IL11 studier
- Cleveland, OH11 studier
- Baltimore, MD11 studier
- Columbus, OH11 studier
Andre studier i Los Angeles
- Ikke-småcellet lungekreft87 studier
- Kreft (alle typer)74 studier
- Brystkreft73 studier
- Prostatakreft61 studier
- Kolorektal kreft59 studier
- Metastatisk kreft57 studier
- Eggstokkreft50 studier
- Lungekreft45 studier
- Plateepitelcancer i hode og hals42 studier
- Pankreaskreft35 studier
- Endometriekreft34 studier
- Melanom34 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.